Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 6.7% - Here's What Happened

Key Points

• Dianthus Therapeutics shares rose by 6.7%, closing at $22.36 after reaching a high of $22.18 during trading.
• Research reports indicate a strong support, with seven analysts rating the stock as "Buy" and an average target price of $53.00.
• The company reported a quarterly loss of ($0.88) earnings per share, missing estimates and earning revenue of only $0.19 million compared to expectations of $0.87 million.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares rose 6.7% during trading on Tuesday . The company traded as high as $22.18 and last traded at $22.36. Approximately 192,090 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 319,745 shares. The stock had previously closed at $20.96.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research reports. William Blair initiated coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating for the company. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Robert W. Baird decreased their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Performance

The stock has a fifty day simple moving average of $19.55 and a two-hundred day simple moving average of $19.97. The stock has a market capitalization of $730.67 million, a price-to-earnings ratio of -6.98 and a beta of 1.43.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently made changes to their positions in DNTH. Hudson Bay Capital Management LP increased its position in shares of Dianthus Therapeutics by 53.9% during the second quarter. Hudson Bay Capital Management LP now owns 115,425 shares of the company's stock worth $2,150,000 after acquiring an additional 40,425 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after acquiring an additional 3,317 shares in the last quarter. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in Dianthus Therapeutics by 19.5% during the 2nd quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company's stock valued at $531,000 after purchasing an additional 4,650 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Dianthus Therapeutics by 3,547.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 49,531 shares of the company's stock valued at $923,000 after purchasing an additional 48,173 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.